Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

This study has been completed.
Sponsor:
Collaborators:
National Ataxia Foundation
Bob Allison Ataxia Research Center (BAARC)
Pfizer
Information provided by (Responsible Party):
Theresa Zesiewicz, University of South Florida
ClinicalTrials.gov Identifier:
NCT00992771
First received: October 8, 2009
Last updated: June 15, 2012
Last verified: June 2012

October 8, 2009
June 15, 2012
October 2009
April 2011   (final data collection date for primary outcome measure)
  • Changes in the patient's SARA Rating Scale total score [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
  • Frequency and severity of dose-limiting adverse events [ Time Frame: 25 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00992771 on ClinicalTrials.gov Archive Site
  • The effect of varenicline on quality of life in patients with spinocerebellar ataxia [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
  • The effect of varenicline on depression and anxiety ratings [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
  • The effect of varenicline on the activity of daily living (ADL) in patients with spinocerebellar ataxia [ Time Frame: 25 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
A Pilot, Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3

Spinocerebellar ataxia (SCA) is a group of inherited disorders characterized by cerebellar degeneration leading to imbalance, incoordination, speech difficulties and problems with walking. Recently, individual case reports have suggested that varenicline, a drug used in smoking cessation, produces substantial improvement in patients with several inherited ataxias. A modest response was noted in 5 patients with SCA, suggesting that it is potentially efficacious in this disorder as well. Although this agent is available for off-label use, the severe side effects noted with its use and the lack of long-term toxicity data demand that it be systematically assessed. The present study will test whether varenicline is safe and potentially efficacious in a heterogeneous cohort of adults with SCA.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Spinocerebellar Ataxia Type 3
  • Drug: varenicline
    up to 1mg BID for 8 weeks
  • Drug: placebo
    placebo matching varenicline, up to 1mg BID for 8 weeks
  • Experimental: Varneicline
    Intervention: Drug: varenicline
  • Placebo Comparator: Placebo
    Intervention: Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
April 2011
April 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Outpatients with spinocerebellar ataxia type 3 diagnosed by a movement disorder specialist and confirmed by genetic testing (of the patient or in a first degree relative of the patient).
  2. Age 18 years to 80 years.
  3. Women of child-bearing potential must use a reliable method of contraception and must provide a negative pregnancy test at entry into the study.
  4. Serum creatine kinase, complete metabolic panel, complete blood count, liver function tests, renal function tests, platelets and EKG are within normal limits (results obtained from primary care physician and dated within the past 6 months or obtained at screening visit).
  5. Stable doses of all medications for 30 days prior to study entry and for the duration of the study.
  6. Ability to ambulate with or without assistance.
  7. Score of 10 or higher (worse) on the SARA total score.
  8. Score of 3 or higher (worse) on the 'gait' subsection of the SARA rating scale.

Exclusion Criteria:

  1. Any unstable illness or concomitant medical condition that, in the investigator's opinion, precludes participation in this study. This includes other disorders that may affect gait or balance (stroke, arthritis, etc).
  2. Pregnancy or lactation.
  3. Concurrent participation in another clinical study.
  4. Patients with a history of substance abuse.
  5. Patients who currently smoke or have smoked within the past 12 months.
  6. Presence of psychosis, bipolar disorder, untreated depression (BDI greater than or equal to 21), or history of suicide attempt.
  7. Concurrent treatment with any MAOIs, Wellbutrin, or nicotine patches.
  8. Dementia or other psychiatric illness that prevents the patient from giving informed consent (Mini Mental Status Exam score less than 24).
  9. Legal incapacity or limited legal capacity.
  10. Presence of severe renal disease (BUN 50% greater than normal or creatinine clearance <60 mL/min) or hepatic disease.
  11. Abnormal creatine kinase and/or platelet count in the past 6 months (as determined by lab reports obtained from primary care physicians or conducted at baseline).
  12. Use of varenicline within the previous 30 days.
  13. Ataxia derived from any other cause than genetically-confirmed SCA (including but not limited to alcoholism, head injury, Multiple Sclerosis, olivo-ponto-cerebellar atrophy or multiple system atrophy).
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00992771
8
Not Provided
Theresa Zesiewicz, University of South Florida
University of South Florida
  • National Ataxia Foundation
  • Bob Allison Ataxia Research Center (BAARC)
  • Pfizer
Principal Investigator: Theresa Zesiewicz, MD University of South Florida
University of South Florida
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP